2024

1. Access to melanoma drugs in Spain: a cross-sectional survey

   Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

   Clinical and Translational Oncology

3. Analysis of Diagnostic Delay and its Impact on Lung Cancer Survival: Results From the Spanish Thoracic Tumor Registry

   Archivos de Bronconeumologia

4. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

   Lung Cancer, Vol. 194

5. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

   European Journal of Cancer, Vol. 208

6. Correction: SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2647-2664), 10.1007/s12094-023-03215-4)

   Clinical and Translational Oncology

7. Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry

   Lung Cancer, Vol. 190

8. Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis

   Journal of Medical Economics, Vol. 27, Núm. 1, pp. 1379-1387

9. Difficulties on the access to innovative targeted therapies for lung cancer in Spain

   Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 597-612

10. Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology

    Clinical and Translational Oncology

11. Genome-wide DNA methylation profiling in tongue squamous cell carcinoma

    Oral Diseases, Vol. 30, Núm. 2, pp. 259-271

12. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

    Clinical and Translational Oncology, Vol. 26, Núm. 8, pp. 1896-1907

13. Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain

    BMJ Open Quality, Vol. 13, Núm. 2

14. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

15. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection

    Cancer Treatment Reviews, Vol. 125

16. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer

    Clinical and Translational Oncology

17. SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2771-2782

18. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)

    Clinical and Translational Oncology, Vol. 26, Núm. 11, pp. 2812-2825

19. Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors’ needs

    Clinical and Translational Oncology

20. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1779-1789